Despite mechanistic and clinical proof-of-concept data, PDE5 inhibition with tadalafil failed to slow the decline in ambulation and mobility in a large Phase 3 trial of boys and young men with DMD 7–14 years of age who were already receiving corticosteroid therapy [17]. This evidence concerns the gene PDE5A and Duchenne muscular dystrophy.